|
市場調查報告書
中東醫藥品市場概要（第2版）：埃及、伊拉克、不丹、黎巴嫩、沙烏地阿拉伯、阿拉伯聯合大公國
Major Pharmaceutical Markets of the Middle East (2nd Ed) An overview of Egypt, Israel, Jordan, Lebanon, Saudi Arabia & UAE
|
中東醫藥品市場概要（第2版）：埃及、伊拉克、不丹、黎巴嫩、沙烏地阿拉伯、阿拉伯聯合大公國 是由出版商Urch Publishing, Ltd.在2009年02月所出版的。
這份英文市場調查報告書包含89 pages 價格從美金2030起跳。
Abstract
"Massive growth is being forecast for the pharmaceutical and biotechnology
markets of Middle Eastern states, driven by moves to liberalise national
economies, the introduction of mass health insurance and the determination of
the region' s governments to become self-sufficient in pharmaceuticals
production."
Major Pharmaceutical Markets of the Middle East (2nd Edition) is a
comprehensive report providing extensive coverage of one of the strongest
emerging markets. Through quality analysis and forecasts, this unique report
will allow you to identify market trends and growth potential opportunities.
This best-selling report provides the necessary background information for a
firm to operate in the region.
Chapter summaries:
- Chapter 1: covers the main characteristics of the Middle Eastern market
through a Political, Economic, Social and Technological (PEST) analysis, plus
insight into the tax environment and Free-Trade Agreements in place or being
negotiated.
- Chapter 2: reports on the Intellectual Property Rights environment of each
of the countries covered.
- Chapter 3: provides a overview of the regional pharmaceutical market, and
includes data on consumption, production, imports, exports, as well as market
forecasts.
The other chapters are in-depth per-country market studies.
Country coverage
- Egypt, the largest pharmaceutical market of the region
- Israel, home to the world' s largest generic drug company
- Jordan, the leading Arab pharmaceutical exporter
- Lebanon, an almost exclusive import market
- Saudi Arabia, the largest market of the Gulf
- The United Arab Emirates, among the highest-priced markets in the region
Five key findings
- Overall the Middle East' s pharmaceutical market is valued at more than
$12bn and is expected to grow at healthy 10-15% annually.
- There are more than 450 pharmaceutical manufacturers in the Middle East -
With the exception of Egypt, all Middle Eastern countries are high importers
of branded drugs. Egypt is over 90% self-sufficient in its medicine needs
- Saudi Arabia, as the richest regional market, has embarked on an ambitious
hospital building project - Major growth drivers are greater access to
generics and innovative new medicines as primary care improves and more people
are covered by health insurance.
- Countries are increasingly adopting liberal economic policies in the
healthcare sector
- Local manufacturing capabilities are constrained to generics.
- A high acceptance of Western medicines is present
What you can learn from this repor
- Which multinationals have invested in the Middle East
- Who are the leading local pharmaceutical manufacturers and distributors
- What are the trends in the pharmaceutical market and import and export
sizes
- How Intellectual Property Rights and patents are the most conflictual
regional issue
- Which countries have implemented health insurance and the likely impact on
growth
- What type of demand and supply-side cost controls are in place
Reasons to purchase the report
- Five-year projected sales figure to enable proprietary forecasting
- Detailed Political, Economic, Social and Technological (PEST) analysis
providing thorough regional and country background
- Extensive list of local contacts to facilitate finding a potential
business partner
- Thorough review of country pharmaceutical markets using latest available
data
- Researched by a native speaker using primary and secondary data
Who should buy the report?
- Chief Executive Officers
- Marketing Directors
- Sales Directors
- Finance Directors
- Head of Commercial Strategy
- Head of Forecasting Unit
- Banking Analysts
- Consultants
Table of Contents
Executive Summary
Chapter 1: Characteristics of the Middle Eastern Pharmaceutical Market: A Political, Economic, Social and Technological (PEST) Analysis
- Political factors
- Economic factors
- Social factors
- Technological factors
- Free trade agreements
- Euro-Mediterranean Free Trade Area (EU-MEFTA)
- US-MEFTA (Middle East Free Trade Agreements)
- Gulf Cooperation Council (GCC)
- Taxation
- Egypt
- Israel
- Jordan
- Lebanon
- Saudi Arabia
- United Arab Emirates
Chapter 2: Intellectual Property Rights
- Trade-related Aspects of Intellectual Property Rights (TRIPS)
- Egypt
- Israel
- Jordan
- Lebanon
- Saudi Arabia
- United Arab Emirates
Chapter 3: Overview of the Middle Eastern Pharmaceutical Market
- Healthcare overview
- Pharmaceutical consumption
- Domestic production
- Imports
- Market forecast
Chapter 4: Egypt
- The healthcare structure
- The pharmaceutical market
- Market figures
- Generics
- Drug pricing and reimbursement
- Distribution
- Cost controls
- Public tenders
- Patient co-payment
- Generic substitution
- Leading companies
Chapter 5: Israel
- The healthcare structure
- The pharmaceutical market
- Market figures
- Drug pricing and reimbursement
- Distribution
- Cost controls
- Prescribing limitations
- Generic substitution
- Patient co-payment
- Leading companies
- Focus/point of interest: Teva
Chapter 6: Jordan
- The healthcare structure
- Health equipment
- The pharmaceutical market
- Market figures
- Focus/point of interest: medical tourism
- Drug pricing and reimbursement
- Distribution
- Cost controls
- Co-payment
- Public-sector procurement
- Leading companies
- Focus/point of interest: Hikma
Chapter 7: Lebanon
- The healthcare structure
- The pharmaceutical market
- Market figures
- Drug pricing and reimbursement
- Distribution
- Cost controls
- Public procurement
- National Drugs Office
- Patient co-payment
- Leading companies
Chapter 8: Saudi Arabia
- The healthcare structure
- Pharmaceutical market
- Market figures
- Drug pricing and reimbursement
- Distribution
- Cost controls
- Private health insurance provision
- ' Dollarisation'
- Gulf Cooperation Council bulk buying
- Leading companies
Chapter 9: United Arab Emirates
- The healthcare structure
- Pharmaceutical market
- Market figures
- Drug pricing and reimbursement
- Distribution
- Cost controls
- Bulk buying
- Co-payment
- Leading companies
- Focus/point of interest: Julphar
- Focus/point of interest: Neopharma
- Focus/point of interest: MENA
Abbreviations
List of Tables
- Table 2.1 Watch List status as at 2008
- Table 3.1 Size of the pharmaceutical markets in selected countries of the
Middle East
- Table 3.2 Largest local pharmaceutical companies
- Table 3.3 Leading generics players based on 2007 sales
- Table 4.1 Egypt' s consumer expenditure on health goods and medical
services (LEm)
- Table 4.2 Egypt' s retail sales of OTC healthcare (LEm)
- Table 5.1 Israel' s consumer expenditure on health goods and medical
services (NISm)
- Table 5.2 Israel' s retail sales of OTC healthcare (NISm)
- Table 5.3 Teva' s sales and net income
- Table 6.1 Jordan' s consumer expenditure on health goods and medical
services (JDm)
- Table 6.2 Jordan' s retail sales of OTC healthcare (JDm)
- Table 7.1 Lebanese retail sales of OTC healthcare (LLm)
- Table 7.2 Lebanese consumer expenditure on health goods and medical
services (LLm)
- Table 8.1 Saudi Arabian consumer expenditure on health goods and medical
services (SRm)
- Table 8.2 Saudi Arabian retail sales of OTC healthcare (SRm)
- Table 9.1 The UAE' s consumer expenditure on health goods and medical
services (AEDm)
- Table 9.2 The UAE' s retail sales of OTC healthcare (AEDm)
- Table 9.3 Julphar sales and profits
|
